These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 26235211)

  • 1. Meeting pragmatism halfway: making a pragmatic clinical trial protocol.
    Rushforth A
    Sociol Health Illn; 2015 Nov; 37(8):1285-98. PubMed ID: 26235211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world evidence: How pragmatic are randomized controlled trials labeled as pragmatic?
    Dal-Ré R; Janiaud P; Ioannidis JPA
    BMC Med; 2018 Apr; 16(1):49. PubMed ID: 29615035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Readiness assessment for pragmatic trials (RAPT): a model to assess the readiness of an intervention for testing in a pragmatic trial.
    Baier RR; Jutkowitz E; Mitchell SL; McCreedy E; Mor V
    BMC Med Res Methodol; 2019 Jul; 19(1):156. PubMed ID: 31319789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pragmatic clinical trials: U.S. payers' views on their value.
    Ratner J; Mullins D; Buesching DP; Cantrell RA
    Am J Manag Care; 2013 May; 19(5):e158-65. PubMed ID: 23781914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of private industry in pragmatic comparative effectiveness trials.
    Buesching DP; Luce BR; Berger ML
    J Comp Eff Res; 2012 Mar; 1(2):147-56. PubMed ID: 24237375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Series: Pragmatic trials and real world evidence: Paper 6. Outcome measures in the real world.
    Welsing PM; Oude Rengerink K; Collier S; Eckert L; van Smeden M; Ciaglia A; Nachbaur G; Trelle S; Taylor AJ; Egger M; Goetz I;
    J Clin Epidemiol; 2017 Oct; 90():99-107. PubMed ID: 28502810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing the design of pragmatic trials: key issues remain.
    Caro JJ; Ishak KJ
    J Comp Eff Res; 2012 Jul; 1(4):319-27. PubMed ID: 24237466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pros and cons of pragmatic clinical trials.
    Lurie JD; Morgan TS
    J Comp Eff Res; 2013 Jan; 2(1):53-8. PubMed ID: 24236521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recommendations for the design of Phase 3 pharmaceutical trials that are more informative for patients, clinicians, and payers.
    Sonnad SS; Mullins CD; Whicher D; Goldsack JC; Mohr PE; Tunis SR
    Contemp Clin Trials; 2013 Nov; 36(2):356-61. PubMed ID: 23999501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy.
    Tunis SR; Stryer DB; Clancy CM
    JAMA; 2003 Sep; 290(12):1624-32. PubMed ID: 14506122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Series: Pragmatic trials and real world evidence: Paper 5. Usual care and real life comparators.
    Zuidgeest MGP; Welsing PMJ; van Thiel GJMW; Ciaglia A; Alfonso-Cristancho R; Eckert L; Eijkemans MJC; Egger M;
    J Clin Epidemiol; 2017 Oct; 90():92-98. PubMed ID: 28694123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Being pragmatic about healthcare complexity: our experiences applying complexity theory and pragmatism to health services research.
    Long KM; McDermott F; Meadows GN
    BMC Med; 2018 Jun; 16(1):94. PubMed ID: 29921277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using the Pragmatic-Explanatory Continuum Indicator Summary (PRECIS) model in clinical research: Application to refine a practice-based research network (PBRN) study.
    Elder WG; Munk N
    J Am Board Fam Med; 2014; 27(6):846-54. PubMed ID: 25381083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Designing, Conducting, Monitoring, and Analyzing Data from Pragmatic Randomized Clinical Trials: Proceedings from a Multi-stakeholder Think Tank Meeting.
    Lentz TA; Curtis LH; Rockhold FW; Martin D; Andersson TLG; Arias C; Berlin JA; Binns C; Cook A; Cziraky M; Dent R; Desai M; Emmett A; Esserman D; George J; Hantel S; Heagerty P; Hernandez AF; Hucko T; Khan N; Lee SF; LoCasale R; Mardekian J; McCall D; Monda K; Normand SL; Riesmeyer J; Roe M; Roessig L; Scott R; Siedentop H; Waldstreicher J; Wang L; Weerakkody G; Wolf M; Ellenberg SS
    Ther Innov Regul Sci; 2020 Nov; 54(6):1477-1488. PubMed ID: 32514736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mobilising modern facts: health technology assessment and the politics of evidence.
    May C
    Sociol Health Illn; 2006 Jul; 28(5):513-32. PubMed ID: 16910945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ethics and Collateral Findings in Pragmatic Clinical Trials.
    Morain SR; Weinfurt K; Bollinger J; Geller G; Mathews DJ; Sugarman J
    Am J Bioeth; 2020 Jan; 20(1):6-18. PubMed ID: 31896322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patients and investigators prefer measures of absolute risk in subgroups for pragmatic randomized trials.
    Murray EJ; Caniglia EC; Swanson SA; Hernández-Díaz S; Hernán MA
    J Clin Epidemiol; 2018 Nov; 103():10-21. PubMed ID: 29966732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Form follows function: pragmatic controlled trials (PCTs) have to answer different questions and require different designs than randomized controlled trials (RCTs).
    Porzsolt F; Eisemann M; Habs M; Wyer P
    Z Gesundh Wiss; 2013 Jun; 21(3):307-313. PubMed ID: 23687408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Per-Protocol Analyses of Pragmatic Trials.
    Hernán MA; Robins JM
    N Engl J Med; 2017 Oct; 377(14):1391-1398. PubMed ID: 28976864
    [No Abstract]   [Full Text] [Related]  

  • 20. Stakeholder perspectives regarding pragmatic clinical trial collateral findings.
    Morain SR; Mathews DJH; Weinfurt K; May E; Bollinger JM; Geller G; Sugarman J
    Learn Health Syst; 2021 Oct; 5(4):e10245. PubMed ID: 34667872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.